Redbiotec achieves milestone and finds new customer
Redbiotech, the Schlieren-Zurich based biotech start-up, has announced a new agreement with a listed, leading biopharmaceutical company. In addition, Redbiotech has reached a milestone in a project with Merck. The deal with Merck was extended.
Redbiotec today that it has closed an agreement with a listed, leading biopharmaceutical company in the field of prime-boost for cancer therapeutics to validate the approach. Christian Schaub, CEO of Redbiotec, states: “This is a major step for Redbiotec and a further proof of Redbiotec’s leadership in the development and production of complex VLPs.” Redbiotec develops VLPs (Virus-like Particles) for three main fields: 1) VLP vaccines, 2) VLPs for prime-boost / enhancement of cancer therapeutics and 3) VLPs, expressing GPCRs and ion channels, as targets for antibody screening.
In addition, Redbiotec has announced that the project started with Merck Sharp & Dohme Corp. (NJ, USA) in October 2011, in which Redbiotec applies its proprietary technology platform rePAX to an undisclosed discovery area, has reached a first milestone successfully and was therefore extended.
Redbiotec is a privately held Swiss Biopharmaceutical Company, based in Zurich-Schlieren. Founded in 2006 as a spin-off of the ETH Zurich, the company won several awards, including the renowned W.A. De Vigier award.
Please login or sign up to comment.
Commenting guidelines